{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:18:19Z","timestamp":1783358299073,"version":"3.54.6"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1442_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Studies providing more evidence to guide adjuvant chemotherapy decisions in colon cancer patients aged 50\u00a0years and older are expected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1442_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients were recruited from the Surveillance, Epidemiology and End Results (SEER) database between 2010 and 2015. The cancer-specific survival (CSS) rate was analyzed using the Kaplan\u2013Meier method, and comparisons of survival difference between different subgroups were performed using the log-rank test. Multivariate Cox proportional hazards regression models were built to assess hazard ratios (HRs) of different variables with 95\u202f% confidence intervals (95\u202f%\u00a0CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1442_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In stage II colon cancer patients aged 50\u00a0years or older, the Kaplan\u2013Meier survival analysis showed that the 5-year CSS rates of chemotherapy and no chemotherapy groups were 83.5 % and 85.6\u202f%, respectively (p=0.0047). Patients with chemotherapy receipt were associated with a higher cancer-specific mortality rate (HR=1.134, 95\u202f% CI: 1.027\u20131.252, p=0.013); however, further subgroup analyses indicated that this finding is highly likely driven by unmeasured confounding and selection bias rather than direct treatment-related harm. For stage III patients of the same age group, 5-year CSS was 74.2\u202f% (chemotherapy) vs. 56.4\u202f% (no chemotherapy, p&lt;0.0001), and chemotherapy was linked to a 49.3\u202f% lower cancer-specific mortality (HR=0.507, 95\u202f% CI: 0.482\u20130.534, p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1442_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjuvant chemotherapy should be considered during the treatment of stage III colon cancer patients aged 50\u00a0years or older. For stage II patients, a generalized survival advantage from chemotherapy was not observed, which highlights the profound impact of selection bias in observational data and strongly emphasizes the necessity of precise, individualized risk stratification before administering treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1442","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:57:12Z","timestamp":1783357032000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of adjuvant chemotherapy in patients with late-onset stage II\/III colon cancer: a retrospective cohort study"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0838-0339","authenticated-orcid":false,"given":"Peng","family":"Song","sequence":"first","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4162-0136","authenticated-orcid":false,"given":"Yongjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-8013","authenticated-orcid":false,"given":"Wencong","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4372-8843","authenticated-orcid":false,"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-1698","authenticated-orcid":false,"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-4857","authenticated-orcid":false,"given":"Chuntao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5066-9882","authenticated-orcid":false,"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of General Surgery , Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University , Tianjin , China"},{"name":"Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center , Tianjin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2026070617004614576_j_med-2026-1442_ref_001","doi-asserted-by":"crossref","unstructured":"Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"2026070617004614576_j_med-2026-1442_ref_002","doi-asserted-by":"crossref","unstructured":"Patel, SG, Karlitz, JJ, Yen, T, Lieu, CH, Boland, CR. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol 2022;7:262\u201374. https:\/\/doi.org\/10.1016\/S2468-1253(21)00426-X.","DOI":"10.1016\/S2468-1253(21)00426-X"},{"key":"2026070617004614576_j_med-2026-1442_ref_003","doi-asserted-by":"crossref","unstructured":"Doubeni, CA. Early-onset colorectal cancer: what reported statistics can and cannot tell us and their implications. Cancer 2019;125:3706\u20138. https:\/\/doi.org\/10.1002\/cncr.32346.","DOI":"10.1002\/cncr.32346"},{"key":"2026070617004614576_j_med-2026-1442_ref_004","doi-asserted-by":"crossref","unstructured":"Tang, CT, Guo, ZX, Wang, P, Chen, YX, Zeng, CY. Higher LNM rate and poorer prognosis of early-onset compared to late-onset T1 stage colorectal cancer: a large-population based study. Am J Cancer Res 2021;11:3176\u201388.","DOI":"10.2139\/ssrn.3820548"},{"key":"2026070617004614576_j_med-2026-1442_ref_005","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Miller, KD, Goding Sauer, A, Fedewa, SA, Butterly, LF, Anderson, JC, et al.. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70:145\u201364. https:\/\/doi.org\/10.3322\/caac.21601.","DOI":"10.3322\/caac.21601"},{"key":"2026070617004614576_j_med-2026-1442_ref_006","doi-asserted-by":"crossref","unstructured":"Gr\u00e1valos, C, Garc\u00eda-Escobar, I, Garc\u00eda-Alfonso, P, Cassinello, J, Mal\u00f3n, D, Carrato, A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transl Oncol 2009;11:526\u201333. https:\/\/doi.org\/10.1007\/s12094-009-0397-8.","DOI":"10.1007\/s12094-009-0397-8"},{"key":"2026070617004614576_j_med-2026-1442_ref_007","doi-asserted-by":"crossref","unstructured":"Arkenau, HT, Bermann, A, Rettig, K, Strohmeyer, G, Porschen, R, Onkologie, AG. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol 2003;14:395\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdg100.","DOI":"10.1093\/annonc\/mdg100"},{"key":"2026070617004614576_j_med-2026-1442_ref_008","doi-asserted-by":"crossref","unstructured":"Moertel, CG, Fleming, TR, Macdonald, JS, Haller, DG, Laurie, JA, Tangen, CM, et al.. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321\u20136. https:\/\/doi.org\/10.7326\/0003-4819-122-5-199503010-00001.","DOI":"10.7326\/0003-4819-122-5-199503010-00001"},{"key":"2026070617004614576_j_med-2026-1442_ref_009","doi-asserted-by":"crossref","unstructured":"Petrelli, F, Labianca, R, Zaniboni, A, Lonardi, S, Galli, F, Rulli, E, et al.. Assessment of duration and effects of 3 vs 6\u00a0months of adjuvant chemotherapy in high-risk stage II colorectal cancer: a subgroup analysis of the TOSCA randomized clinical trial. JAMA Oncol 2020;6:547\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6486.","DOI":"10.1001\/jamaoncol.2019.6486"},{"key":"2026070617004614576_j_med-2026-1442_ref_010","doi-asserted-by":"crossref","unstructured":"Ramai, D, Ofosu, A, Lai, JK, Gao, ZH, Adler, DG. Fibrolamellar hepatocellular carcinoma: a population-based observational study. Dig Dis Sci 2021;66:308\u201314. https:\/\/doi.org\/10.1007\/s10620-020-06135-3.","DOI":"10.1007\/s10620-020-06135-3"},{"key":"2026070617004614576_j_med-2026-1442_ref_011","doi-asserted-by":"crossref","unstructured":"Edge, SB, Compton, CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471\u20134. https:\/\/doi.org\/10.1245\/s10434-010-0985-4.","DOI":"10.1245\/s10434-010-0985-4"},{"key":"2026070617004614576_j_med-2026-1442_ref_012","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Kratzer, TB, Giaquinto, AN, Sung, H, Jemal, A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45. https:\/\/doi.org\/10.3322\/caac.21871.","DOI":"10.3322\/caac.21871"},{"key":"2026070617004614576_j_med-2026-1442_ref_013","doi-asserted-by":"crossref","unstructured":"Wagle, NS, Nogueira, L, Devasia, TP, Mariotto, AB, Yabroff, KR, Islami, F, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin 2025;75:308\u201340. https:\/\/doi.org\/10.3322\/caac.70011.","DOI":"10.3322\/caac.70011"},{"key":"2026070617004614576_j_med-2026-1442_ref_014","doi-asserted-by":"crossref","unstructured":"Malvezzi, M, Carioli, G, Bertuccio, P, Boffetta, P, Levi, F, La Vecchia, C, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol 2018;29:1016\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdy033.","DOI":"10.1093\/annonc\/mdy033"},{"key":"2026070617004614576_j_med-2026-1442_ref_015","doi-asserted-by":"crossref","unstructured":"Al-Refaie, WB, Parsons, HM, Henderson, WG, Jensen, EH, Tuttle, TM, Vickers, SM, et al.. Major cancer surgery in the elderly: results from the American College of Surgeons National Surgical Quality Improvement Program. Ann Surg 2010;251:311\u201318. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b6b04c.","DOI":"10.1097\/SLA.0b013e3181b6b04c"},{"key":"2026070617004614576_j_med-2026-1442_ref_016","doi-asserted-by":"crossref","unstructured":"Heald, RJ, Ryall, RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479\u201382. https:\/\/doi.org\/10.1016\/s0140-6736(86)91510-2.","DOI":"10.1016\/S0140-6736(86)91510-2"},{"key":"2026070617004614576_j_med-2026-1442_ref_017","doi-asserted-by":"crossref","unstructured":"Hohenberger, W, Weber, K, Matzel, K, Papadopoulos, T, Merkel, S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009;11:354\u201365. https:\/\/doi.org\/10.1111\/j.1463-1318.2008.01735.x.","DOI":"10.1111\/j.1463-1318.2008.01735.x"},{"key":"2026070617004614576_j_med-2026-1442_ref_018","doi-asserted-by":"crossref","unstructured":"Kim, NK, Kim, YW, Han, YD, Cho, MS, Hur, H, Min, BS, et al.. Complete mesocolic excision and central vascular ligation for colon cancer: principle, anatomy, surgical technique, and outcomes. Surg Oncol 2016;25:252\u201362. https:\/\/doi.org\/10.1016\/j.suronc.2016.05.009.","DOI":"10.1016\/j.suronc.2016.05.009"},{"key":"2026070617004614576_j_med-2026-1442_ref_019","doi-asserted-by":"crossref","unstructured":"Buczacki, SJ, Davies, RJ. Colon resection: is standard technique adequate? Surg Oncol Clin 2014;23:25\u201334. https:\/\/doi.org\/10.1016\/j.soc.2013.09.003.","DOI":"10.1016\/j.soc.2013.09.003"},{"key":"2026070617004614576_j_med-2026-1442_ref_020","doi-asserted-by":"crossref","unstructured":"Xu, HB, Huang, F, Su, R, Shen, FM, Lv, QZ. Capecitabine plus oxaliplatin\u00a0(XELOX) compared with 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of\u00a0randomized controlled trials. Eur J Clin Pharmacol 2015;71:589\u2013601. https:\/\/doi.org\/10.1007\/s00228-015-1828-9.","DOI":"10.1007\/s00228-015-1828-9"},{"key":"2026070617004614576_j_med-2026-1442_ref_021","doi-asserted-by":"crossref","unstructured":"Famurewa, AC, Mukherjee, AG, Wanjari, UR, Sukumar, A, Murali, R, Renu, K, et al.. Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs. Life Sci 2022;305:120789. https:\/\/doi.org\/10.1016\/j.lfs.2022.120789.","DOI":"10.1016\/j.lfs.2022.120789"},{"key":"2026070617004614576_j_med-2026-1442_ref_022","doi-asserted-by":"crossref","unstructured":"Sinicrope, FA, Sargent, DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012;18:1506\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1469.","DOI":"10.1158\/1078-0432.CCR-11-1469"},{"key":"2026070617004614576_j_med-2026-1442_ref_023","doi-asserted-by":"crossref","unstructured":"Jin, L, Xiao, J, Luo, Y, Duan, L, Gong, Y, Li, Y, et al.. Exploring gut microbiota in systemic lupus erythematosus: insights and biomarker discovery potential. Clin Rev Allergy Immunol 2025;68:42. https:\/\/doi.org\/10.1007\/s12016-025-09051-4.","DOI":"10.1007\/s12016-025-09051-4"},{"key":"2026070617004614576_j_med-2026-1442_ref_024","doi-asserted-by":"crossref","unstructured":"Gong, Y, Jin, L, Duan, L, Xiao, J, Li, Y, Wang, H, et al.. Extracellular vesicles derived from Streptococcus anginosus aggravate lupus nephritis by triggering TLR2-MyD88-NF-\u03baB signalling in NK cells. J\u00a0Extracell Vesicles 2025;14:e70134. https:\/\/doi.org\/10.1002\/jev2.70134.","DOI":"10.1002\/jev2.70134"},{"key":"2026070617004614576_j_med-2026-1442_ref_025","doi-asserted-by":"crossref","unstructured":"Gong, Y, Duan, L, Xiao, J, Deng, Y, Wang, H, Zhang, Y, et al.. Extracellular vesicles of Streptococcus anginosus mediate gastritis via epithelial barrier disruption and macrophage-driven inflammation. Adv Sci 2026;13:e202512494. https:\/\/doi.org\/10.1002\/advs.202512494.","DOI":"10.1002\/advs.202512494"},{"key":"2026070617004614576_j_med-2026-1442_ref_026","doi-asserted-by":"crossref","unstructured":"Wen, M, Wang, J, Ou, Z, Nie, G, Chen, Y, Li, M, et al.. Bacterial extracellular vesicles: a position paper by the Microbial Vesicles Task Force of the Chinese Society for Extracellular Vesicles. Interdiscip Med 2023;1:e20230017. https:\/\/doi.org\/10.1002\/INMD.20230017.","DOI":"10.1002\/inmd.12046"},{"key":"2026070617004614576_j_med-2026-1442_ref_027","doi-asserted-by":"crossref","unstructured":"Zhang, Z, Huang, D, Feng, J, Li, W, Wang, Z, Lu, M, et al.. PDE5 inhibitors against cancer via mediating immune cells in tumor microenvironment: AI\u2010based approach for future drug repurposing exploration. Interdiscipl Med 2024;2:e20230062. https:\/\/doi.org\/10.1002\/INMD.20230062.","DOI":"10.1002\/INMD.20230062"},{"key":"2026070617004614576_j_med-2026-1442_ref_028","doi-asserted-by":"crossref","unstructured":"Wu, N, Ma, S, Liu, X, Zhao, M, Sun, N, Wang, R, et al.. TROP2-guided aggregation-induced emission-luminogen nanoparticles overcome sacituzumab govitecan resistance via mitochondrial oxidative stress and immunogenic cell death in triple-negative breast cancer. Interdiscip Med 2025;3:e70073. https:\/\/doi.org\/10.1002\/INMD.70073.","DOI":"10.1002\/inmd.70073"},{"key":"2026070617004614576_j_med-2026-1442_ref_029","doi-asserted-by":"crossref","unstructured":"Yan, X, Shang, W, Ren, H, Cai, Y, Gong, Y, Wang, L, et al.. Intelligent\u00a0responsive degradation nanoplatform with aggregation-induced emission for hypoxic tumors multimodal phototheranostics and\u00a0overcoming PD-L1 resistance. Chem Eng J 2025;526:171050. https:\/\/doi.org\/10.1016\/j.cej.2025.171050.","DOI":"10.1016\/j.cej.2025.171050"},{"key":"2026070617004614576_j_med-2026-1442_ref_030","doi-asserted-by":"crossref","unstructured":"Gong, Y, Lin, W, Fang, X, Zhang, R, Luo, M, Wu, H, et al.. Advances in cellular immune theranostic approaches for glioblastoma: current trends and future directions. Cancer Innov 2025;4:e70018. https:\/\/doi.org\/10.1002\/cai2.70018.","DOI":"10.1002\/cai2.70018"},{"key":"2026070617004614576_j_med-2026-1442_ref_031","doi-asserted-by":"crossref","unstructured":"Wu, N, Yang, N, Zhang, S, Wu, H, Fang, X, Lin, W, et al.. Chimeric antigen receptor NK cells for breast cancer immunotherapy. Cancer Treat Rev 2025;137:102943. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102943.","DOI":"10.1016\/j.ctrv.2025.102943"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1442\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1442\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:01:44Z","timestamp":1783357304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1442\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,6]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1442"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1442","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261442"}}